Wilbur Pan

1.4k total citations · 2 hit papers
19 papers, 783 citations indexed

About

Wilbur Pan is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Wilbur Pan has authored 19 papers receiving a total of 783 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Oncology, 8 papers in Cancer Research and 5 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Wilbur Pan's work include Cancer Immunotherapy and Biomarkers (17 papers), Breast Cancer Treatment Studies (7 papers) and Colorectal Cancer Treatments and Studies (4 papers). Wilbur Pan is often cited by papers focused on Cancer Immunotherapy and Biomarkers (17 papers), Breast Cancer Treatment Studies (7 papers) and Colorectal Cancer Treatments and Studies (4 papers). Wilbur Pan collaborates with scholars based in United States, Spain and United Kingdom. Wilbur Pan's co-authors include Javier Cortés, Peter Schmid, Norikazu Masuda, Marco Torregroza Otero, Carlos H. Barrios, Mastura Md Yusof, Vassiliki Karantza, Hiroji Iwata, Sherene Loi and Seock‐Ah Im and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and JNCI Journal of the National Cancer Institute.

In The Last Decade

Wilbur Pan

18 papers receiving 773 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer

2022 594 citations Javier Cortés, Hope S. Rugo et al. New England Journal of Medicine profile →
Event-free survival by residual cancer burden with pembrolizumab in early-stage TNBC: exploratory analysis from KEYNOTE-522

2024 47 citations Lajos Pusztai, Carsten Denkert et al. Annals of Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Wilbur Pan United States	8	614	246	231	178	115	19	783
Marco Torregroza Otero Spain	6	651 1.1×	233 0.9×	258 1.1×	198 1.1×	104 0.9×	7	800
Anh Nguyen Duc Switzerland	7	797 1.3×	361 1.5×	237 1.0×	239 1.3×	91 0.8×	15	925
Esther Holgado Spain	15	757 1.2×	169 0.7×	367 1.6×	207 1.2×	129 1.1×	42	870
Shilpen Patel United States	9	989 1.6×	422 1.7×	344 1.5×	287 1.6×	219 1.9×	20	1.3k
Theresa Link Germany	13	501 0.8×	310 1.3×	184 0.8×	101 0.6×	190 1.7×	55	754
Mario Liste-Hermoso United States	4	633 1.0×	298 1.2×	192 0.8×	181 1.0×	88 0.8×	7	756
James W. Smithy United States	11	538 0.9×	105 0.4×	205 0.9×	265 1.5×	146 1.3×	41	691
Ignacio Matos Spain	17	521 0.8×	89 0.4×	206 0.9×	145 0.8×	195 1.7×	57	818
Elvire Pons‐Tostivint France	13	468 0.8×	134 0.5×	351 1.5×	86 0.5×	238 2.1×	47	764
Reshma Mahtani United States	14	438 0.7×	194 0.8×	229 1.0×	40 0.2×	142 1.2×	80	630

Countries citing papers authored by Wilbur Pan

Since Specialization

Citations

This map shows the geographic impact of Wilbur Pan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Wilbur Pan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Wilbur Pan more than expected).

Fields of papers citing papers by Wilbur Pan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Wilbur Pan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Wilbur Pan. The network helps show where Wilbur Pan may publish in the future.

Co-authorship network of co-authors of Wilbur Pan

This figure shows the co-authorship network connecting the top 25 collaborators of Wilbur Pan. A scholar is included among the top collaborators of Wilbur Pan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Wilbur Pan. Wilbur Pan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

Pusztai, Lajos, Carsten Denkert, Joyce O’Shaughnessy, et al.. (2024). Event-free survival by residual cancer burden with pembrolizumab in early-stage TNBC: exploratory analysis from KEYNOTE-522. Annals of Oncology. 35(5). 429–436. 47 indexed citations breakdown →

Im, Seock‐Ah, Javier Cortés, David W. Cescon, et al.. (2024). Results from the randomized KEYNOTE-355 study of pembrolizumab plus chemotherapy for Asian patients with advanced TNBC. npj Breast Cancer. 10(1). 79–79. 5 indexed citations

Dent, Rebecca, et al.. (2024). 24TiP A phase III, randomized study of adjuvant sacituzumab tirumotecan (sac-TMT) plus pembrolizumab vs treatment of physician’s choice (TPC) in patients with TNBC who received neoadjuvant therapy and did not achieve a pathological complete response (pCR) at surgery. Annals of Oncology. 35. S1413–S1413.

Haiderali, Amin, et al.. (2024). Pembrolizumab plus chemotherapy for first-line treatment of advanced triple-negative breast cancer. Future Oncology. 20(22). 1587–1600. 7 indexed citations

Schmid, Peter, Javier Cortés, Rebecca Dent, et al.. (2024). Abstract LBO1-01: Neoadjuvant pembrolizumab or placebo plus chemotherapy followed by adjuvant pembrolizumab or placebo for early-stage triple-negative breast cancer: Updated event-free survival results from the phase 3 KEYNOTE-522 study. Cancer Research. 84(9_Supplement). LBO1–1. 5 indexed citations

Dent, Rebecca, Javier Cortés, Lajos Pusztai, et al.. (2024). Neoadjuvant pembrolizumab plus chemotherapy/adjuvant pembrolizumab for early-stage triple-negative breast cancer: quality-of-life results from the randomized KEYNOTE-522 study. JNCI Journal of the National Cancer Institute. 116(10). 1654–1663. 11 indexed citations

Huang, Min, Peter A. Fasching, Amin Haiderali, et al.. (2023). Cost-Effectiveness of Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Single-Agent Pembrolizumab for High-Risk Early-Stage Triple-Negative Breast Cancer in the United States. Advances in Therapy. 40(3). 1153–1170. 14 indexed citations

Cortés, Javier, Amin Haiderali, Min Huang, et al.. (2023). Neoadjuvant immunotherapy and chemotherapy regimens for the treatment of high-risk, early-stage triple-negative breast cancer: a systematic review and network meta-analysis. BMC Cancer. 23(1). 792–792. 13 indexed citations

Hattori, Masaya, Norikazu Masuda, Toshimi Takano, et al.. (2023). Pembrolizumab plus chemotherapy in Japanese patients with triple‐negative breast cancer: Results from KEYNOTE‐355. Cancer Medicine. 12(9). 10280–10293. 17 indexed citations

10.

Huang, Min, Peter A. Fasching, Amin Haiderali, et al.. (2023). Association Between Event-Free Survival and Overall Survival in Early-Stage Triple-Negative Breast Cancer. Future Oncology. 20(6). 335–348. 1 indexed citations

11.

McArthur, Heather L., Javier Cortés, Rebecca Dent, et al.. (2023). Abstract PD3-01: Neoadjuvant pembrolizumab + chemotherapy vs placebo + chemotherapy followed by adjuvant pembrolizumab vs placebo for early TNBC: Post hoc analysis of adjuvant radiation therapy in the phase 3 KEYNOTE-522 study. Cancer Research. 83(5_Supplement). PD3–1. 5 indexed citations

12.

Takano, Toshimi, Javier Cortés, David W. Cescon, et al.. (2022). PS2-2 KEYNOTE-355 Asian subset: Pembrolizumab + chemotherapy vs placebo + chemotherapy for triple-negative breast cancer. Annals of Oncology. 33. S465–S465. 1 indexed citations

13.

Cortés, Javier, Hope S. Rugo, David W. Cescon, et al.. (2022). Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer. New England Journal of Medicine. 387(3). 217–226. 594 indexed citations breakdown →

14.

Huang, Min, Joyce O’Shaughnessy, Amin Haiderali, et al.. (2022). Q-TWiST analysis of pembrolizumab combined with chemotherapy as first-line treatment of metastatic triple-negative breast cancer that expresses PD-L1. European Journal of Cancer. 177. 45–52. 6 indexed citations

15.

Huang, Min, et al.. (2022). HSR22-146: Health Utility in Patients With Previously Untreated Locally Recurrent Inoperable or Metastatic TNBC. Journal of the National Comprehensive Cancer Network. 20(3.5). HSR22–146. 1 indexed citations

16.

Pusztai, Lajos, Carsten Denkert, Joyce O’Shaughnessy, et al.. (2022). Event-free survival by residual cancer burden after neoadjuvant pembrolizumab + chemotherapy versus placebo + chemotherapy for early TNBC: Exploratory analysis from KEYNOTE-522.. Journal of Clinical Oncology. 40(16_suppl). 503–503. 35 indexed citations

17.

Haiderali, Amin, et al.. (2022). HSR22-145: Pembrolizumab Plus Chemotherapy for First-Line Treatment of Advanced Triple-Negative Breast Cancer – A Network Meta-Analysis. Journal of the National Comprehensive Cancer Network. 20(3.5). HSR22–145. 2 indexed citations

18.

Cortés, Javier, David W. Cescon, Hope S. Rugo, et al.. (2022). Abstract GS1-02: Final results of KEYNOTE-355: Randomized, double-blind, phase 3 study of pembrolizumab + chemotherapy vs placebo + chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer. Cancer Research. 82(4_Supplement). GS1–2. 7 indexed citations

19.

Huang, Min, Peter A. Fasching, Amin Haiderali, et al.. (2022). Cost–Effectiveness of Pembrolizumab Plus Chemotherapy as First-Line Treatment in PD-L1-Positive Metastatic Triple-Negative Breast Cancer. Immunotherapy. 14(13). 1027–1041. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact